Update 2:40pm: Adds ANI Pharma response, updates shares. Alimera Sciences (NASDAQ:ALIM) pared an earlier drop to 6% after it said it filed a lawsuit against ANI Pharmaceuticals (ANIP) to compel ...

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

While reporting financial results for the third quarter on Friday, biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) raised ...

the Company completed the acquisition of Alimera Sciences. The transaction significantly expands the scope and scale of ANI’s ...

Piper initiated with an Overweight rating and a price target of $68. Earlier this year, ANI Pharmaceuticals acquired Alimera Sciences for $5.50 per share in cash and one non-tradable contingent ...

With ophthalmology assets Iluvien and Yutiq added from the company's recent acquisition of Alimera Sciences, ANI's (ANIP) rare disease portfolio should make up more than 45% of the company's ...

ANI’s Estradiol Gel ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words “believe ...

ANI is focused on delivering sustainable growth by scaling up ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are ...

"With the FDA approval and commercialization of Estradiol Gel, 0.06%, we are pleased to bring another limited-competition ...

ANI’s Estradiol Gel ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words ...